Additional information
| Trade Name | Resihance |
|---|---|
| Generic Name | Regorafenib |
| Manufacturer | Bayer Zydus plc |
| Drug Type | Oncology |
| Indication | Rectal Cancer / GI Tumor |
| Doasage Form | Tablet |
| Packaging | 28 Tablets |
RESIHANCE (Regorafenib)-40mg
Regorafenib (Resihance) is in a class of medications called kinase inhibitors that bind to tyrosine kinase receptors and inhibit epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF), receptors on the surface of the cell. By binding to these receptors regorafenib blocks an important pathway that promotes cell division.
It is indicated for the treatment of patients with metastatic colorectal cancer (CRC) and it is also indicated for the treatment of patients with locally advanced, unresectable, or metastatic gastrointestinal stromal tumor (GIST).
